Insider · CIK 0002112438
Nikhil Aneja
Files at ALGS (Aligos Therapeutics, Inc.). First filing -, latest -.
In brief
Nikhil Aneja files SEC Form 4 as officer at ALGS (Aligos Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Nikhil Aneja has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | ALGS Aligos Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +9,450 | $0.00 | $0 | 9,450 | Mar 11, 2026 |
Questions about Nikhil Aneja
Answered from the filings on this page, as of the latest one.
Is Nikhil Aneja buying or selling?
Nikhil Aneja has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Nikhil Aneja's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Nikhil Aneja has 0.
Where does Nikhil Aneja file Form 4?
Nikhil Aneja has filed Form 4 at ALGS (Aligos Therapeutics, Inc.) as Principal Accounting Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.